| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SRRA | Common Stock | Exercise of in-the-money or at-the-money derivative security | $4.95M | +375K | +33% | $13.20 | 1.51M | Jan 26, 2022 | See footnotes (4), | F1 |
| transaction | SRRA | Common Stock | Exercise of in-the-money or at-the-money derivative security | $742K | +56.2K | +33% | $13.20 | 227K | Jan 26, 2022 | See footnotes (4), | F2 |
| transaction | SRRA | Common Stock | Exercise of in-the-money or at-the-money derivative security | $742K | +56.2K | +33% | $13.20 | 227K | Jan 26, 2022 | See footnotes | F3, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SRRA | Series B Warrants | Exercise of in-the-money or at-the-money derivative security | $0 | -375K | -100% | $0.00* | 0 | Jan 26, 2022 | Common Stock | 375K | $13.20 | See footnotes | F1, F4, F5, F6 |
| transaction | SRRA | Series B Warrants | Exercise of in-the-money or at-the-money derivative security | $0 | -56.2K | -100% | $0.00* | 0 | Jan 26, 2022 | Common Stock | 56.2K | $13.20 | See footnotes | F2, F4, F6, F7 |
| transaction | SRRA | Series B Warrants | Exercise of in-the-money or at-the-money derivative security | $0 | -56.2K | -100% | $0.00* | 0 | Jan 26, 2022 | Common Stock | 56.2K | $13.20 | See footnotes | F3, F4, F6, F8 |
| Id | Content |
|---|---|
| F1 | These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII. |
| F2 | These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis. |
| F3 | These securities are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM. |
| F4 | Each of the Reporting Person, OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. |
| F5 | Consists of Series B warrants previously held by OPI VII. |
| F6 | The expiration date of the warrants is the date on the seventy-fifth (75th) day anniversary of the announcement by the Issuer, via publicly disseminated press release or SEC filing, of the top-line data results from MOMENTUM, its Phase 3 clinical trial of momelotinib for patients with myelofibrosis. |
| F7 | Consists of Series B warrants previously held by OPM. |
| F8 | Consists of Series B warrants previously held by Genesis. |